{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.3","upperLimit":"16.3","value":"12.7"},{"groupId":"OG001","lowerLimit":"14.3","upperLimit":"28.6","value":"18.2"},{"groupId":"OG002","lowerLimit":"12.3","upperLimit":"40.2","value":"17.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"27"}],"units":"Participants"}],"description":"Overall Survival (OS) was defined as the time from first dose until death due to any cause. If a patient was not known to have died at the time of analysis cut-off, OS was censored at the date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who have relapsed or progressed after receiving at least one line of prior anti-cancer therapy for metastatic disease received dabrafenib 150 mg BID. It was continued until disease progression or death or unacceptable AEs or investigator discretion to discontinue or decision to crossover from monotherapy to combination therapy.","id":"OG000","title":"Cohort A (Dabrafenib Monotherapy)"},{"description":"Participants who had received 1-3 prior lines of systemic anti-cancer therapies for advanced stage/metastatic disease received Dabrafenib 150 mg BID and Trametinib 2 mg once daily (OD). Treatment continued until disease progression, death, or unacceptable AEs or investigator discretion to discontinue.","id":"OG001","title":"Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD"},{"description":"Participants who had not received any prior systemic anti-cancer for metastatic disease therapies were given Dabrafenib 150 mg BID and Trametinib 2 mg OD. Treatment continued until disease progression, death, or unacceptable AEs or at investigator discretion to discontinue.","id":"OG002","title":"Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD"}],"paramType":"MEDIAN","populationDescription":"All Treated Population (ATP). No separate OS analysis was conducted for cross over patient, as they were included in Cohort A (Dabrafenib Monotherapy Second-Line Plus).","reportingStatus":"POSTED","timeFrame":"From study treatment start date until date of of death from any cause, assessed up to approximately 113 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}